The potential clinical value of Biktarvy® in HIV treatment in China

Abstract

Abstract: Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide), a new integrase strand transfer inhibitor (INSTI)- based single tablet regimen (STR), has been recommended as a first-line antiretroviral therapy (ART) by European and American guidelines in 2018. It has also been recommended by American guidelines as one of the first-line options for rapid initiation of ART. Biktarvy® a good safety profile and a high resistance barrier in clinical trials is demonstrated non-inferior efficacy to existing first-line ART regimens, a good safety profile and a high resistance barrier in clinical trials. It has been approved and used clinically in the European Union (EU), the United States of America (USA) and some regions in Asia. This paper reviews the efficacy and safety data from Biktarvy’s pivotal trials, and discusses the potential clinical significance of this novel regimen for the treatment of Chinese patients with human immunodeficiency viruses (HIV) infection.

Key words: Bictegravir, Integrase strand transfer inhibitor, HIV, Antiretroviral therapy

WANG Hui. The potential clinical value of Biktarvy® in HIV treatment in China[J]. Electronic Journal of Emerging Infectious Diseases, 2019, 4(2): 85-90.

References

[1] Gilead Science.Biktarvy US Prescribing Information[M]. Washington: FDA, 2018: 15-26.
[2] US Department of Health & Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV [EB/OL].https://www.cdc.gov/mmwr/preview/mmwrhtml/00054080.htm.
[3] Saag MS, Benson CA, Gandhi RT, et al.Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel[J]. JAMA, 2018, 320(4): 379-396.
[4] European AIDS Clinical Society. EACS Guidelines(Version 9.1.)[S/OL]. http://www.eacsociety.org/files/guidelines_9.1-english.pdf.
[5] Gallant J, Lazzarin A, Mills A, et al.Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial[J]. Lancet, 2017, 390(10107): 2063-2072.
[6] Sax PE, Pozniak A, Montes ML, et al.Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial[J]. Lancet, 2017, 390(10107): 2073-2082.
[7] Molina JM, Ward D, Brar I, et al.Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial[J]. Lancet HIV, 2018, 5(7): e357-e65.
[8] Daar ES, Dejesus E, Ruane P, et al.Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial[J]. Lancet HIV, 2018, 5(7): e347-e56.
[9] Andreatta K, Willkom M, Martin R, et al.Resistance Analyses of Bictegravir/Emtricitabine/Tenofovir Alafenamide Switch Studies [C]. proceedings of the Conference on Retroviruses and Opportunistic Infections. Boston, MA. 2018. Resistance Analyses of Bictegravir/Emtricitabine/Tenofovir Alafenamide Switch Studies [C]. proceedings of the Conference on Retroviruses and Opportunistic Infections. Boston, MA. 2018. http://www.croiconference.org/sessions/resistance-analyses-bictegraviremtricitabinetenofovir-alafenamide-switch-studies
[10] Rockstroh JK, Sax PE, Daar ES, et al.High HBV and HIV Suppression With Treatment of HIV/HBV Coinfection in B/F/TAF Studies [C]. proceedings of the Conference on Retroviruses and Opportunistic Infections. Boston, MA. 2018. High HBV and HIV Suppression With Treatment of HIV/HBV Coinfection in B/F/TAF Studies [C]. proceedings of the Conference on Retroviruses and Opportunistic Infections. Boston, MA. 2018. http://www.croiconference.org/sessions/high-hbv-and-hiv-suppression-treatment-hivhbv-coinfection-bftaf-studies
[11] Chua J. B/F/TAF Switch Study for HIV-HBV Coinfection (BEST-HBV) [M]. ClinicalTrials.gov.2019. https://clinicaltrials.gov/ct2/show/NCT03797014
[12] Gilead Sciences. Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults (Alliance) [M]. ClinicalTrials.gov.2019. https://clinicaltrials.gov/ct2/show/NCT03547908
[13] Gilead Sciences. Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women [M]. ClinicalTrials.gov.2019. https://clinicaltrials.gov/ct2/show/NCT02652624
[14] Gaur AH, Rodriguez C, Mcgrath EJ, et al.Bictegravir/FTC/TAF Single-Tablet Regimen in Adolescents: Week-24 Results [C]. proceedings of the Conference on Retroviruses and Opportunistic Infections. Boston, MA. 2018. Bictegravir/FTC/TAF Single-Tablet Regimen in Adolescents: Week-24 Results [C]. proceedings of the Conference on Retroviruses and Opportunistic Infections. Boston, MA. 2018. http://www.croiconference.org/sessions/bictegravirftctaf-single-tablet-regimen-adolescents-week-24-results
[15] Cotton M, Liberty A, Rodriguez CA, et al.Pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) single‐tablet regimen in HIV‐1‐infected children (6 to <12 years); proceedings of the AIDS, Amsterdam, NL, 2018 [C]. Pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) single‐tablet regimen in HIV‐1‐infected children (6 to <12 years); proceedings of the AIDS, Amsterdam, NL, 2018 [C]. http://www.natap.org/2018/IAC/IAC_39.htm
[16] Weldring T, Smith SMS.Patient-Reported Outcomes (pROs) and Patient-Reported Outcome Measures (pROMs)[J]. Health Serv Insights, 2013, (6): 61-8.
[17] Wohl D, Clarke A, Maggiolo F, et al.Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine[J]. PATIENTS 2018, 11(5): 561-73.
[18] Tsiang M, Jones GS, Goldsmith J, et al.Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile[J]. Antimicrob Agents Chemother, 2016, 60(12): 7086-97.
[19] White K, Niedziela-Majka A, Novikov N, et al.Bictegravir Dissociation Half-life from HIV-1 G140S/Q148H Integrase-DNA Complexes [M]. proceedings of the Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, WA. 2017. Bictegravir Dissociation Half-life from HIV-1 G140S/Q148H Integrase-DNA Complexes [M]. proceedings of the Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, WA. 2017. http://www.croiconference.org/sessions/bictegravir-dissociation-half-life-hiv-1-g140sq148h-integrasedna-complexes
[20] White K, Cihlar T, Miller MD.Potent Activity of Bictegravir (BIC; GS-9883), a Novel Unboosted HIV-1 Integrase Strand Transfer Inhibitor (INSTI), Against Patient Isolates with INSTI-Resistance [M]. proceedings of the 14th European Workshop on HIV & Hepatitis. Rome, Italy. 2016. Potent Activity of Bictegravir (BIC; GS-9883), a Novel Unboosted HIV-1 Integrase Strand Transfer Inhibitor (INSTI), Against Patient Isolates with INSTI-Resistance [M]. proceedings of the 14th European Workshop on HIV & Hepatitis. Rome, Italy. 2016. http://www.natap.org/2016/HIV/062316_01.htm
[21] 金霞,熊燃,王丽艳,等. 2010-2014年我国HIV感染病例的晚发现情况分析[J]. 中国流行病学杂志,2016,37(2): 218-21.
[22] 卢洪洲,李太生.整合酶抑制剂临床应用专家共识[J]. 上海医药,2018,39(23):19-25.
[23] 魏秀青,张园园,贺健梅,等. 湖南省6558例HIV/AIDS病人HAART疗效及不良反应分析[J]. 中国艾滋病性病,2014,(8): 559-562.
[24] 中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防控制中心. 中国艾滋病诊疗指南(2018版)[J]. 新发传染病电子杂志,2019,4(2): 65-84.
[25] AIDSinfo. HIV and Opportunistic Infections, Coinfections,Conditions [M].2018. https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/26/89/hiv-and-hepatitis-b.
[26] 丁莉莎,张国强,江洋,等. 湖南省HIV患者合并感染HBV及HCV现状调查及风险因素分析[J]. 中国病毒病杂志,2011,1(5): 358-362.
[27] 冯丹,姚添,程雁鹏,等. 艾滋病病毒感染者合并乙型肝炎病毒感染现状及其相关因素研究[J]. 中华流行病学杂志,2017, 38(12):1624-1628.
[28] 孙建军,卢洪洲. HIV合并HBV感染之治疗进展[J]. 中国艾滋病性病,2015,(4):346-348.
[29] 李航,张福杰,卢洪洲,等. HIV感染合并慢性肾脏病患者管理专家共识[J]. 中国艾滋病性病, 2017, 23(6): 578-581.
[30] ViiV Healthcare. Triumeq Prescribing Information[M]. Washington: FDA, 2017: 25-36.
[31] Levin J, Heather Zhang, Shao Y, et al.The Effect of Hepatic or Renal Impairment on Bictegravir Pharmacokinetics [M]. 18th International Workshop on Clinical Pharmacology of Antiviral Therapy. Chicago, Ill.C; National AIDS Treatment Advocacy Project. 2017. The Effect of Hepatic or Renal Impairment on Bictegravir Pharmacokinetics [M]. 18th International Workshop on Clinical Pharmacology of Antiviral Therapy. Chicago, Ill.C; National AIDS Treatment Advocacy Project. 2017. http://www.natap.org/2017/Pharm/Pharm_31.htm.
[32] Gilead Sciences.Genvoya Prescribing Information[M]. Washington: FDA, 2019: 36-42.